Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

722.93 -9.27 (-1.27%)
Streaming Delayed Price Updated: 11:08 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Why Is MicroCloud Hologram (HOLO) Stock Up 31% Today?
MicroCloud Hologram stock is up on Wednesday with heavy trading of HOLO shares ahead of a potential AI catalyst next week. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 No-Brainer Stocks I'd Add to the "Magnificent Seven"
They fit right in. 
Via The Motley Fool
LLY Stock Alert: You Can Now Get Eli Lilly’s Weight Loss Drugs on Amazon
Eli Lilly stock is on the move Wednesday morning as investors in LLY shares learn about a new pharmacy partnership with Amazon! 
Via InvestorPlace
Obesity Drugs On Amazon - Eli Lilly Partners With Amazon's Pharmacy Unit To Deliver Drug Prescriptions, Including Popular Zepbound For Weight Loss
Amazon Pharmacy integrates LillyDirect, offering home delivery of diabetes, obesity, and migraine medications. Enhance access with prompt doorstep delivery by trusted providers. Eli Lilly's partnership... 
Via Benzinga
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking aims to enter a market that may be worth $100 billion in a few years. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Behind the Scenes of Eli Lilly and Co's Latest Options Trends
Via Benzinga
Is Eli Lilly the Best Pharmaceutical Stock for You?
Lilly's recently approved weight-loss drug is off to a good start. 
Via The Motley Fool
Jim Cramer Says Tuesday Rally Was Driven By Nvidia, Eli Lilly And Other 'Stocks Reacting Positively To Good Earnings Per Share News'
CNBC's Jim Cramer has highlighted three stocks that are showing signs of recovery after facing consecutive losses. 
Via Benzinga
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseeing stock surge amid clinical milestones. Analysis compares PD-1 agonist... 
Via Benzinga
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way. 
Via The Motley Fool
Meet the Unknown Small-Cap Company That's Been Paying a Dividend for at Least 66 Years Longer Than Coca-Cola, ExxonMobil, and Eli Lilly
A relatively tiny company ($508 million market cap) that most investors have never heard of has been doling out a consecutive dividend for over two centuries -- including 104 years longer than... 
Via The Motley Fool
Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic — 'Shame, Blame And The Weight Loss Revolution'
Future Fund co-founder Gary Black shared details about Oprah Winfrey's upcoming TV special discussing her weight loss journey and the use of GLP-1 weight loss drugs, potentially impacting stocks of... 
Via Benzinga
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does. 
Via The Motley Fool
Meet the 5 Stocks That Have Contributed Almost All of the S&P 500's 2024 Gains
These companies have contributed the lion's share of the S&P 500's 7% year-to-date gain. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights. 
Via The Motley Fool
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest. 
Via The Motley Fool
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
The Best Stocks to Invest $50,000 in Right Now
These stalwart companies can help you grow your wealth. 
Via The Motley Fool
S&P 500 Soars To New Highs: 5 Best Stocks Ytd
Many semiconductor ETFs also touched new 52-week highs. 
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
Why Eli Lilly Stock Flopped on Friday
An important new drug's potential approval has been pushed back, and the timing is unclear. 
Via The Motley Fool
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies — Or Could They Get Another Lift?
Weight loss drugs could get an increased spotlight with a television special from legendary TV host Oprah Winfrey. 
Via Benzinga
Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk
Novo Nordisk stock slumped despite winning FDA approval for its Wegovy in reducing cardiovascular risks. 
Via Investor's Business Daily
Exposures Product Safety
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BenevolentAI CEO Dr Joerg Moeller discusses AI's impact on drug discovery
--News Direct-- 
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review
The Nasdaq and S&P 500 hit new all-time highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA... 
Via Benzinga
Exposures Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab. 
Via Investor's Business Daily
Exposures Product Safety
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.